| |
Explore dynamic forces reshaping how therapies reach patients and gain actionable insights on market access and patient support from industry experts in this podcast series from Asembia's AXS25 Summit. Listen now.
|
|
Today’s Big NewsMay 5, 2025 |
|
| Wednesday, May 14, 2025 | 11am ET / 8am PTBiotech success isn’t just about great science—it’s about building a compelling commercial narrative from day one. Join us to explore how early commercialization planning, powered by real-world insights, can maximize an asset’s potential. Our discussion will uncover strategies to integrate commercial thinking into R&D. Register now. |
|
| By Darren Incorvaia Johnson & Johnson bought the full rights to a rare disease gene therapy a few years ago, but now the Big Pharma may be feeling buyer’s remorse. The treatment failed to improve the vision-guided mobility of patients with the eye disease X-linked retinitis pigmentosa (XLRP) in a phase 3 trial, the company announced in a May 2 release. |
|
|
|
By Gabrielle Masson Deerfield Management has unveiled the third installment of its healthcare innovations fund, earmarking more than $600 million for promising therapeutics and technologies. |
By Darren Incorvaia Vertex Pharmaceuticals is no longer developing adeno-associated viruses as gene therapy vectors, a company spokesperson confirmed with Fierce Biotech. |
Sponsored by 89bio How a commonly “silent disease” is driving urgency and novelty in the liver disease treatment paradigm and what can we hope for. |
|
No matter where you are in your biologics development journey, you need reliable, high-quality analytical data to move forward with confidence. Our full-spectrum analytical testing services are designed to meet your evolving needs, from early to late stage clinical and beyond.
|
|
By Gabrielle Masson,Darren Incorvaia As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. |
By Gabrielle Masson The leaked drafts have proven true. President Donald Trump’s proposed federal budget for 2026 would nearly halve funds for the National Institutes of Health, dropping the agency’s financing from about $48 billion to $27 billion. |
By Fraiser Kansteiner Recursion is “deprioritizing” three clinical-stage programs, pausing another and winding down a single preclinical program in an undisclosed target, the company revealed in its first-quarter financial results Monday. The biotech said it will specifically look to either discontinue the programs or pass them on via partnerships. |
By Angus Liu Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after reporting what one analyst called “impressive” overall survival data. |
By Darren Incorvaia Eighteen years ago, Tim Friede began willingly injecting himself with escalating doses of venom from 16 snake species. Now, antibodies in his blood have led to the development of a three-part antivenom cocktail capable of protecting mice from the toxins of 19 dangerous snakes. |
By Emma Beavins President Trump sent his annual budget request to congressional appropriators on Friday morning. The document is a wish list for the discretionary spending cuts the executive branch wishes to see Congress make in annual appropriations. |
By Eric Sagonowsky BioNTech is making plans to debut on the commercial oncology scene. Part of that effort involves mapping out a larger manufacturing footprint. |
Fierce podcastsDon’t miss an episode |
| | Two journalists, one name and a candid conversation—Angus Liu and Angus Chen talk cancer reporting, racial identity and being mistaken for each other. |
|
|---|
|
|
|
Thursday, May 15, 2025 | 12pm ET / 9am PT Join this webinar for a deep dive into today’s biotech investment climate and practical strategies to navigate commercialization when pharma partnerships are delayed or uncertain.
|
|
| WhitepaperDon’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
| Whitepaper Learn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Learn how the SpyTag/SpyCatcher protein ligation system was engineered into SpyLock technology to streamline bispecific antibody generationDiscover how SpyLock technology reduces workload by enabling rapid bispecific assembly and accelerating candidate selectionExplore a real-world case study of constructing anti-PD1/PD-L1 bispecific antibodies using SpyLock for functional screening.Sponsored by: Bio-Rad |
| WhitepaperWe interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| eBookTypical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
| |
|
